Asthma therapeutics market size was valued at USD 28.15 billion in 2024 and is expected to reach USD 41.79 billion by 2032, growing at a CAGR of 5.07% over the forecast period of 2025-2032.
Asthma is a chronic respiratory condition whose frequency is gradually increasing in response to urbanization, air pollution, and climate change, affecting millions of people globally.
For instance, the World Health Organization (WHO) estimates that asthma affects over 262 million people globally and results in more than 450,000 deaths yearly.
The Centers for Disease Control and Prevention (CDC) estimated that, in 2024, 25 million Americans, including 6 million children, were suffering from asthma. Reflecting a strong regulatory drive to increase treatment alternatives, the U.S. Food and Drug Administration (FDA) has lately sped approvals for new asthma therapeutics. Together with rising healthcare expenditure and better diagnosis techniques, these government-led projects are driving strong asthma therapeutics market growth and influencing new asthma therapeutics market trends.
High asthma prevalence, good reimbursement policies, and quick acceptance of biologics for asthma and digital health solutions fuel the leadership in the global Asthma therapeutics market. With a CAGR of 8.46%, the U.S. asthma therapeutics market alone is expected to rise to USD 16.31 billion by 2032 from USD 11.18 billion in 2024. The ongoing FDA approvals for new drugs, including the recent approval of depemokimab for review as an ultra-long-acting biologic for type 2 inflammation asthma, and the clearance of new inhaled therapies, such as frevecitinib for patients inadequately controlled by standard treatments, further support the predominance of the U.S. market.
With over 262 million affected and more than 450,000 annual fatalities globally, asthma continues to be a serious public health issue, according to the WHO. In 2024, the CDC estimates 25 million Americans, including 6 million children, have asthma. The FDA has stepped up its initiatives to hasten the approval of biologics and smart inhalers, among sophisticated asthma therapies. While rising healthcare expenditure and better diagnosis techniques continue to improve outcomes in the asthma therapeutics market, national agencies and organizations, such as the Asthma and Allergy Foundation of America (AAFA) are driving awareness and access to treatment.
Drivers:
Asthma Therapeutics is Transformed, and Clinical Outcomes are Improved by Biologics and Personalized Medicine Innovations
Offering customized solutions for patients with severe or treatment-resistant forms of the condition, breakthroughs in biologics and personalized medicine are transforming asthma therapy. The U.S. FDA's approval of the biologics license application for depemokimab, which should be approved, will become the first ultra-long-acting biologic for asthma and will need just two doses annually. Depemokimab greatly lessened asthma flare-ups and hospitalizations in individuals with type 2 inflammation, according to clinical trials (SWIFT and ANCHOR), therefore underscoring the potential of focused treatments to improve patient outcomes and adherence.
Furthermore, expected to boost patient access and lower costs for those with moderate to severe asthma is the FDA's approval of Omlyclo (omalizumab-igec) as the first interchangeable biosimilar to Xolair. Digital health technology, such as smart inhalers and remote monitoring systems, which are progressively embraced in North America and Europe to maximize adherence and enable data-driven, individualized treatment, which further complements these developments. Driven by better access to biologics, digital health advancements, and value-based reimbursement models linking drug cost to patient outcomes, the U.S. asthma treatment market is expected to expand at a noteworthy CAGR. These scientific and legal turning points are drastically changing the asthma therapeutics scene and increasing the availability and efficacy of advanced, customized treatment.
Restraints:
Underdiagnosis and Poor Adherence Undermine Asthma Therapeutics Effectiveness and Limit Market Expansion
Persistent underdiagnosis and suboptimal adherence to asthma therapies significantly undermine the effectiveness of available treatments and restrict market growth. Despite advancements in diagnosis and therapy, many individuals remain undiagnosed or are not optimally managed, resulting in preventable exacerbations and increased healthcare utilization. In the U.S., asthma-related mortality, which had been declining, saw a sharp increase from 2018 to 2020, with notable rise among younger age groups and persistent disparities affecting females and non-Hispanic Black populations.
Poor adherence to prescribed regimens is exacerbated by complex dosing schedules, side effects, and inadequate patient education. The integration of digital health solutions, such as smart inhalers and remote monitoring systems, is beginning to address these challenges by providing real-time adherence tracking and personalized feedback. However, disparities in access to digital tools and healthcare infrastructure, especially in rural and low-resource settings, continue to limit their impact. Addressing these issues through widespread education, improved diagnostic protocols, and expanded digital health adoption is essential for maximizing the benefits of Asthma Therapeutics and achieving sustainable market growth.
By Drug Class
The anti-inflammatory segment dominated the market with a revenue share of 61% in 2024, particularly for lowering airway inflammation and thereby preventing exacerbations. Anti-inflammatory medications, especially inhaled corticosteroids (ICS), are fundamental in asthma treatment. Government figures showing the increasing frequency of severe and allergic asthma, particularly in young populations, support the leadership in this segment.
For instance, the U.S. FDA recently approved several biologics for asthma, including depemokimab-an ultra-long-acting IL-5 inhibitor for type 2 inflammation, also under review for use in children.
Biologics for asthma, including omalizumab and mepolizumab, are increasingly prescribed for severe and allergic asthma therapeutics market segments, offering targeted control of airway inflammation and reducing hospitalizations. Recent advances include the FDA's approval of novel medications, including frevecitinib, which targets individuals, inadequately controlled by long-acting beta agonists (LABAs) and traditional ICS. Particularly for people with allergen-triggered asthma or eosinophilic phenotypes, these developments are revolutionizing choices for the treatment of severe asthma.
Expected to achieve the fastest CAGR of 5.57% over the projected period are combination asthma therapies, especially those combining ICS with LABAs or triple combos (ICS/LABA/LAMA). Superior efficacy drives this since combination treatments treat bronchoconstriction and airway inflammation, therefore enhancing the results for patients using treatments for severe and allergic asthma. Reflecting good clinical evidence, national and international recommendations now call for combination asthma therapies for moderate-to-severe and pediatric asthma drugs. The FDA’s recent approval of combination inhalers and biologics, such as AstraZeneca's Tezepelumab, which showed a notable drop in Phase III studies' exacerbations. Targeting treatments and smart inhalers, which allow customised dose and adherence tracking, helps to justify the trend towards individualised asthma treatment.
By product
Inhalers remain the dominant segment in the market and held the highest asthma therapeutics share in 2024, due to their convenience, portability, and quick relief for both chronic respiratory disease treatments and acute exacerbations. The standard of treatment is now inhaled corticosteroids (ICS), bronchodilator drugs, and combination asthma treatments used widely through inhalers. Recent government statistics and legislative changes show how quickly smart inhalers are being adopted. The global smart inhalers market is estimated to reach USD 5.30 billion in 2032 and increase at a CAGR of 14.01% during the forecast period. Recently approved by the U.S. FDA, novel inhaled treatments and combination inhalers, include Trelegy Ellipta for patients not responding to dual therapy, drive market development. As the CDC and AAFA underline, inhalers are still the recommended option for juvenile asthma medications because of their simplicity and dose precision.
Nebulizers are expected to register the fastest CAGR, driven by their essential part in severe asthma treatment options and for small children or elderly patients struggling with inhaler technique. More portable and effective nebulizers, due to technological developments, have improved access for severe instances and asthma driven by allergens. Government projects, including nebulizer donation campaigns in India and the acceptance of nebulizers in home and hospital environments, are accelerating segment growth. Targeting individuals whose asthma is not sufficiently managed by current inhaled maintenance medications, the FDA's clearance of frevecitinib for clinical trials in 2025 shows continuous innovation in inhalation drug delivery for both inhalers and nebulizers.
By Route of Administration
The inhaled segment dominated the asthma treatment market, comprising 46% of the asthma therapeutics market share in 2024. The segment’s growth is propelled by the inhaled corticosteroids (ICS) to the lungs, directly provide bronchodilator drugs and minimize systemic side effects, making inhaled treatments preferred for quick relief and minimizing side effects. For both severe asthma treatment choices and the allergic asthma therapeutics market, the FDA and international guidelines advise inhaled treatments as first-line therapy. The development of digital adherence tools and smart inhalers improves patient outcomes and supports tailored asthma treatment.
Particularly for pediatric asthma drugs and those who find it difficult to use inhalers, the oral segment is expected to see the largest asthma therapeutics market growth. While systemic corticosteroids are crucial for severe asthma treatment choices and acute exacerbations, leukotriene receptor antagonists are extensively prescribed for the allergic asthma therapeutics market, especially in children. Under development are new oral immunomodulatory drugs and biologics for asthma, hence increasing the available treatments for refractory cases. Recent advances include the FDA's evaluation of oral and inhaled biologics and the inclusion of oral treatments into combo regimens for complete management of asthma.
With a 51% market share in 2024, North America dominated the global asthma therapeutics market. The region’s dominance is driven by the strong research and development investment, superior healthcare infrastructure, and high asthma frequency, the U.S. leads this region. The U.S. asthma therapeutics market alone was valued at USD 11.18 billion in 2024, and is expected to grow at a CAGR of 4.84% during the forecast period.
Strong reimbursement systems, high diagnostic rates, and broad availability of advanced treatments as smart inhalers and biologics, help to justify this supremacy. By accelerating the approval of sophisticated asthma medications, the U.S. FDA has been proactive, thus strengthening its leadership in the field of asthma therapy. Furthermore, greatly enhanced patient adherence and outcomes are continuous awareness programs headed by groups, such as the Asthma and Allergy Foundation of America (AAFA) and the incorporation of digital health solutions, such as smart inhalers and telemedicine.
Asia Pacific is predicted to be the fastest-growing region in the asthma therapeutics market with a 5.7% CAGR over the forecast period. Attributed to rapid urbanization, increasing air pollution levels, and better diagnostic techniques, countries including China and India are witnessing a boost in recorded asthma cases. Government projects, including national asthma control campaigns and more respiratory care funding, are driving market development even more. Along with the increasing presence of global pharmaceutical businesses, the area is also seeing more availability of generic asthma drugs. Asia Pacific is destined to become a major development engine for the worldwide Asthma Therapeutics sector as economic conditions improve, public knowledge of asthma management rises, and healthcare access grows.
In 2024 Europe accounted for a significant share of the global asthma therapeutics market. The creation of creative targeted drugs drives the expansion of the area, especially as limits in conventional treatments become clearer. Well-established healthcare systems, high diagnostic rates, government-supported access to sophisticated biologics, and combo treatments help European nations to grow. European regulatory bodies keep pushing for the acceptance of fresh treatment approaches, thereby promoting market expansion and patient outcomes.
The key asthma therapeutics companies are GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Covis Pharma, F. Hoffmann-La Roche Ltd., BD, AstraZeneca, Sanofi, Koninklijke Philips N.V., Boehringer Ingelheim International GmbH, and others.
Reflecting the agency's dedication to hastening access to breakthrough medications, GlaxoSmithKline got enhanced FDA approval for its triple-combining inhaler Trelegy Ellipta in January 2025, now authorized for asthma patients resistant to dual treatment.
Following clearance from the European Medicines Agency (EMA), Sanofi and Regeneron debuted a new dose formulation of Dupixent® (dupilumab), an IL-4 and IL-13-targeting biologic, enhancing access for patients with moderate-to-severe asthma in September 2024.
In January 2025, GlaxoSmithKline received expanded FDA approval for its triple-combination inhaler Trelegy Ellipta, now indicated for asthma patients unresponsive to dual therapy, reflecting the agency’s commitment to accelerating access to advanced therapies.
| Report Attributes | Details |
|---|---|
| Market Size in 2024 | USD 28.15 Billion |
| Market Size by 2032 | USD 41.79 Billion |
| CAGR | CAGR of 5.07% From 2025 to 2032 |
| Base Year | 2024 |
| Forecast Period | 2025-2032 |
| Historical Data | 2021-2023 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Product (Inhalers {Dry Powder, Metered Dose, Soft Mist}, and Nebulizers) • By Drug Class (Anti-inflammatory, Combination Therapy, and Bronchodilators) • By Route of Administration (Inhaled, Oral, and Others) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Covis Pharma, F. Hoffmann-La Roche Ltd., BD, AstraZeneca, Sanofi, Koninklijke Philips N.V., Boehringer Ingelheim International GmbH, and others |
Ans. The projected market size for the asthma therapeutics market is USD 41.79 billion by 2032.
Ans: The North America region dominated the asthma therapeutics market in 2024.
Ans. The CAGR of the asthma therapeutics market is 5.07% during the forecast period of 2025-2032.
Ans: Underdiagnosis and poor adherence undermine asthma therapeutics' effectiveness and limit market expansion
Ans: The anti-inflammatory segment dominated the Asthma Therapeutics Market.
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Prescription Trends by Region (2024)
5.2 Drug Volume Analysis – Production & Usage
5.3 Healthcare Spending on Asthma Management (2024)
5.4 Treatment Adherence and Medication Access Rates
5.5 Regulatory and Approvals Landscape (2024)
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new Product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Small-Scale LNG Market Segmentation By Product
7.1 Chapter Overview
7.2 Inhalers
7.2.1 Inhalers Market Trends Analysis (2021-2032)
7.2.2 Inhalers Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.3 Dry Powder
7.2.3.1 Dry Powder Market Trends Analysis (2021-2032)
7.2.3.2 Dry Powder Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.4 Metered Dose
7.2.4.1 Metered Dose Market Trends Analysis (2021-2032)
7.2.4.2 Metered Dose Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.5 Soft Mist
7.2.5.1 Soft Mist Market Trends Analysis (2021-2032)
7.2.5.2 Soft Mist Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Nebulizers
7.3.1 Nebulizers Market Trends Analysis (2021-2032)
7.3.2 Nebulizers Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Small-Scale LNG Market Segmentation By Drug Class
8.1 Chapter Overview
8.2 Anti- inflammatory
8.2.1 Anti- inflammatory Market Trend Analysis (2021-2032)
8.2.2 Anti- inflammatory Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Combination Therapy
8.3.1 Combination Therapy Market Trends Analysis (2021-2032)
8.3.2 Combination Therapy Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Bronchodilators
8.4.1 Bronchodilators Market Trends Analysis (2021-2032)
8.4.2 Bronchodilators Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Small-Scale LNG Market Segmentation By Route of Administration
9.1 Chapter Overview
9.2 Inhaled
9.2.1 Inhaled Market Trends Analysis (2021-2032)
9.2.2 Inhaled Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3 Oral
9.3.1 Oral Market Trends Analysis (2021-2032)
9.3.2 Oral Market Size Estimates and Forecasts to 2032 (USD Billion)
9.4 Others
9.4.1 Others Market Trends Analysis (2021-2032)
9.4.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America Small-Scale LNG Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.2.3 North America Small-Scale LNG Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.2.4 North America Small-Scale LNG Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.2.5 North America Small-Scale LNG Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.2.6 USA
10.2.6.1 USA Small-Scale LNG Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.2.6.2 USA Small-Scale LNG Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.2.6.3 USA Small-Scale LNG Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.2.7 Canada
10.2.7.1 Canada Small-Scale LNG Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.2.7.2 Canada Small-Scale LNG Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.2.7.3 Canada Small-Scale LNG Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.2.8 Mexico
10.2.8.1 Mexico Small-Scale LNG Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.2.8.2 Mexico Small-Scale LNG Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.2.8.3 Mexico Small-Scale LNG Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.3 Europe
10.3.1 Trends Analysis
10.3.2 Europe Small-Scale LNG Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.3.3 Europe Small-Scale LNG Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.3.4 Europe Small-Scale LNG Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.3.5 Europe Small-Scale LNG Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.3.6 Germany
10.3.6.1 Germany Small-Scale LNG Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.3.6.2 Germany Small-Scale LNG Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.3.6.3 Germany Small-Scale LNG Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.3.7 France
10.3.7.1 France Small-Scale LNG Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.3.7.2 France Small-Scale LNG Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.3.7.3 France Small-Scale LNG Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.3.8 UK
10.3.8.1 UK Small-Scale LNG Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.3.8.2 UK Small-Scale LNG Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.3.8.3 UK Small-Scale LNG Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.3.9 Italy
10.3.9.1 Italy Small-Scale LNG Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.3.9.2 Italy Small-Scale LNG Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.3.9.3 Italy Small-Scale LNG Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.3.10 Spain
10.3.10.1 Spain Small-Scale LNG Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.3.10.2 Spain Small-Scale LNG Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.3.10.3 Spain Small-Scale LNG Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.3.11 Poland
10.3.11.1 Poland Small-Scale LNG Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.3.11.2 Poland Small-Scale LNG Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.3.11.3 Poland Small-Scale LNG Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.3.12 Turkey
10.3.12.1 Turkey Small-Scale LNG Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.3.12.2 Turkey Small-Scale LNG Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.3.12.3 Turkey Small-Scale LNG Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.3.13 Rest of Europe
10.3.13.1 Rest of Europe Small-Scale LNG Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.3.13.2 Rest of Europe Small-Scale LNG Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.3.13.3 Rest of Europe Small-Scale LNG Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.4 Asia Pacific
10.4.1 Trends Analysis
10.4.2 Asia Pacific Small-Scale LNG Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.4.3 Asia Pacific Small-Scale LNG Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.4.4 Asia Pacific Small-Scale LNG Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.4.5 Asia Pacific Small-Scale LNG Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.4.6 China
10.4.6.1 China Small-Scale LNG Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.4.6.2 China Small-Scale LNG Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.4.6.3 China Small-Scale LNG Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.4.7 India
10.4.7.1 India Small-Scale LNG Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.4.7.2 India Small-Scale LNG Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.4.7.3 India Small-Scale LNG Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.4.8 Japan
10.4.8.1 Japan Small-Scale LNG Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.4.8.2 Japan Small-Scale LNG Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.4.8.3 Japan Small-Scale LNG Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.4.9 South Korea
10.4.9.1 South Korea Small-Scale LNG Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.4.9.2 South Korea Small-Scale LNG Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.4.9.3 South Korea Small-Scale LNG Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.4.10 Singapore
10.4.10.1 Singapore Small-Scale LNG Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.4.10.2 Singapore Small-Scale LNG Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.4.10.3 Singapore Small-Scale LNG Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.4.11 Australia
10.4.11.1 Australia Small-Scale LNG Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.4.11.2 Australia Small-Scale LNG Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.4.11.3 Australia Small-Scale LNG Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.4.12 Rest of Asia Pacific
10.4.12.1 Rest of Asia Pacific Small-Scale LNG Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.4.12.2 Rest of Asia Pacific Small-Scale LNG Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.4.12.3 Rest of Asia Pacific Small-Scale LNG Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.5 Middle East and Africa
10.5.1 Trends Analysis
10.5.2 Middle East and Africa Small-Scale LNG Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.5.3 Middle East and Africa Small-Scale LNG Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.5.4 Middle East and Africa Small-Scale LNG Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.5.5 Middle East and Africa Small-Scale LNG Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.5.6 UAE
10.5.6.1 UAE Small-Scale LNG Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.5.6.2 UAE Small-Scale LNG Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.5.6.3 UAE Small-Scale LNG Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.5.7 Saudi Arabia
10.5.7.1 Saudi Arabia Small-Scale LNG Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.5.7.2 Saudi Arabia Small-Scale LNG Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.5.7.3 Saudi Arabia Small-Scale LNG Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.5.8 Saudi Arabia
10.5.8.1 Saudi Arabia Small-Scale LNG Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.5.8.2 Saudi Arabia Small-Scale LNG Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.5.8.3 Saudi Arabia Small-Scale LNG Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.5.9 Qatar
10.5.9.1 Qatar Small-Scale LNG Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.5.9.2 Qatar Small-Scale LNG Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.5.9.3 Qatar Small-Scale LNG Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.5.10 South Africa
10.5.10.1 South Africa Small-Scale LNG Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.5.10.2 South Africa Small-Scale LNG Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.5.10.3 South Africa Small-Scale LNG Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.5.11 Rest of Middle East & Africa
10.5.11.1 Rest of Middle East & Africa Small-Scale LNG Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.5.11.2 Rest of Middle East & Africa Small-Scale LNG Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.5.11.3 Rest of Middle East & Africa Small-Scale LNG Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America Small-Scale LNG Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.6.3 Latin America Small-Scale LNG Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.6.4 Latin America Small-Scale LNG Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.6.5 Latin America Small-Scale LNG Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.6.6 Brazil
10.6.6.1 Brazil Small-Scale LNG Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.6.6.2 Brazil Small-Scale LNG Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.6.6.3 Brazil Small-Scale LNG Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.6.7 Argentina
10.6.7.1 Argentina Small-Scale LNG Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.6.7.2 Argentina Small-Scale LNG Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.6.7.3 Argentina Small-Scale LNG Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
10.6.8 Rest of Latin America
10.6.8.1 Rest of Latin America Small-Scale LNG Market Estimates and Forecasts, By Product (2021-2032) (USD Billion)
10.6.8.2 Rest of Latin America Small-Scale LNG Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.6.8.3 Rest of Latin America Small-Scale LNG Market Estimates and Forecasts, By Route of Administration (2021-2032) (USD Billion)
11. Company Profiles
11.1 GlaxoSmithKline plc
11.1.1 Company Overview
11.1.2 Financial
11.1.3 Product/ Services Offered
11.1.4 SWOT Analysis
11.2 Teva Pharmaceutical Industries Ltd.
11.2.1 Company Overview
11.2.2 Financial
11.2.3 Product/ Services Offered
11.2.4 SWOT Analysis
11.3 Merck & Co., Inc.
11.3.1 Company Overview
11.3.2 Financial
11.3.3 Product/ Services Offered
11.3.4 SWOT Analysis
11.4 Covis Pharma
11.4.1 Company Overview
11.4.2 Financial
11.4.3 Product/ Services Offered
11.4.4 SWOT Analysis
11.5 F. Hoffmann-La Roche Ltd.
11.5.1 Company Overview
11.5.2 Financial
11.5.3 Product/ Services Offered
11.5.4 SWOT Analysis
11.6 BD
11.6.1 Company Overview
11.6.2 Financial
11.6.3 Product/ Services Offered
11.6.4 SWOT Analysis
11.7 AstraZeneca
11.7.1 Company Overview
11.7.2 Financial
11.7.3 Product/ Services Offered
11.7.4 SWOT Analysis
11.8 Sanofi
11.8.1 Company Overview
11.8.2 Financial
11.8.3 Product/ Services Offered
11.8.4 SWOT Analysis
11.9 Koninklijke Philips N.V.
11.9.1 Company Overview
11.9.2 Financial
11.9.3 Product/ Services Offered
11.9.4 SWOT Analysis
11.10 Boehringer Ingelheim International GmbH
11.10.1 Company Overview
11.10.2 Financial
11.10.3 Product/ Services Offered
11.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
By Product
Inhalers
Dry Powder
Metered Dose
Soft Mist
Nebulizers
By Drug Class
Anti- inflammatory
Combination Therapy
Bronchodilators
By Route of Administration
Inhaled
Oral
Others
Request for Segment Customization as per your Business Requirement: Segment Customization Request
North America
US
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Poland
Turkey
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
UAE
Saudi Arabia
Qatar
South Africa
Rest of Middle East & Africa
Latin America
Brazil
Argentina
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players
